Sanofi

ORI Capital exits its investment in Kymab to Sanofi in a $1.1B deal, announces $400M ORI Fund II

ORI Capital exits investment in Kymab to Sanofi in a $1.1B deal, announces upcoming $400M ORI Fund II

Hong Kong-based healthcare fund management firm ORI Capital has decided to exit Kymab, a British biopharmaceutical company that specializes in vaccines and novel drug solutions.…

Perspectives: Who Pays for HealthTech?

Note: This session was the second in the three-part series "Asia’s Most Wanted—Digital Health" organised by BlueChilli HealthTech and TechNode Global.    The global…